I THINK TO TREAT A FABRIC SITE WITH NEGATIVE PRESSURE; AND SYSTEMS, APPLIANCES AND METHODS

专利摘要:
It is a dressing to treat a negative pressure fabric site that may comprise a cover that has an adhesive, a transmitter, a perforated polymer film and a perforated silicone gel that has an opening for treatment. The cover, transmitter, perforated polymer film and perforated silicone gel can be mounted in a stacked relationship with the cover and perforated silicone gel by closing the transmitter. The perforated polymer film can be at least partially exposed through the treatment opening, and at least part of the adhesive can be exposed through the perforated silicone around the treatment opening.
公开号:BR112019025029A2
申请号:R112019025029-8
申请日:2018-06-05
公开日:2020-06-23
发明作者:Brian Locke Christopher；Christopher Brian Locke；Mark Robinson Timothy；Timothy Mark Robinson
申请人:Kci Licensing, Inc；
IPC主号:

专利说明:

[0001] [0001] This application claims the benefit, provided in title 35 USC § 119 (e), of filing Provisional Patent Application serial number US 62 / 650.572, entitled "ASSEMBLY FEATURES AND METHODS FOR A PEEL-AND-PLACE DRESSING FOR USE WITH NEGATIVE-PRESSURE TREATMENT, "filed March 30, 2018; Provisional Patent Application serial number U.S. 62 / 633,438, entitled "COMPOSITE DRESSINGS FOR IMPROVED GRANULATION AND REDUCED MACERATION WITH NEGATIVE- PRESSURE TREATMENT," filed February 21, 2018; Provisional Patent Application U.S. serial number 62 / 623,325, entitled "METHODS FOR MANUFACTURING AND ASSEMBLING DUAL MATERIAL TISSUE INTERFACE FOR NEGATIVE-PRESSURE THERAPY," filed January 29, 2018; Provisional Patent Application U.S. serial number 62 / 625,704, entitled "CUSTOMIZABLE COMPOSITE DRESSINGS FOR IMPROVED GRANULATION AND REDUCED MACERATION WITH NEGATIVE-PRESSURE TREATMENT," filed February 2, 2018; Provisional Patent Application U.S. serial number 62 / 616,244, entitled "COMPOSITE DRESSINGS FOR IMPROVED GRANULATION AND REDUCED MACERATION WITH NEGATIVE-PRESSURE TREATMENT," filed January 11, 2018; Provisional Patent Application U.S. serial number 62 / 615,821, entitled "METHODS FOR MANUFACTURING AND ASSEMBLING DUAL MATERIAL TISSUE INTERFACE FOR NEGATIVE- PRESSURE THERAPY," filed January 10, 2018; Provisional Patent Application U.S. serial number 62 / 613,494, entitled "PEEL AND PLACE DRESSING FOR THICK EXUDATE AND INSTILLATION," filed January 4, 2018; Provisional Patent Application U.S. serial number 62 / 592,950, entitled "MULTI-LAYER WOUND FILLER FOR EXTENDED WEAR TIME," filed November 30, 2017; Provisional Patent Application serial number U.S. 62 / 576,498, entitled "SYSTEMS, APPARATUSES, AND METHODS FOR NEGATIVE-PRESSURE TREATMENT WITH REDUCED TISSUE IN-GROWTH," filed October 24, 2017; Provisional Patent Application serial number U.S. 62 / 565,754, entitled "COMPOSITE DRESSINGS FOR IMPROVED GRANULATION AND REDUCED MACERATION WITH NEGATIVE-PRESSURE TREATMENT," filed September 29, 2017; Provisional Patent Application U.S. serial number 62 / 516,540, entitled "TISSUE CONTACT INTERFACE," filed June 7, 2017; Provisional Patent Application U.S. serial number 62 / 516,550, entitled "COMPOSITE DRESSINGS FOR IMPROVED GRANULATION AND REDUCED MACERATION WITH NEGATIVE-PRESSURE TREATMENT," filed June 7, 2017; and Provisional Patent Application serial number US 62 / 516,566, entitled "COMPOSITE DRESSINGS FOR IMPROVED GRANULATION AND REDUCED MACERATION WITH NEGATIVE- PRESSURE TREATMENT," filed on June 7, 2017, each of which is incorporated into this document by reference title for all purposes. TECHNICAL FIELD
[0002] [0002] The invention presented in the appended claims relates, in general, to tissue treatment systems and, more particularly, but without limitation, to dressings for fabric treatment and methods of using dressings to treat fabric with negative pressure. BACKGROUND
[0003] [0003] Studies and clinical practices have shown that reducing pressure near a tissue site can increase and accelerate the growth of new tissue at the tissue site. There are numerous applications for this phenomenon, but they have proved to be particularly advantageous for treating injuries. Regardless of the aetiology of an injury, be it trauma, surgery or another reason, proper care of the injury is important to the outcome. The treatment of wounds or other tissues with reduced pressure may be commonly called “negative pressure therapy”, but it is also known by other names, including “negative pressure injury therapy”, “reduced pressure therapy”, “vacuum therapy ”,“ Vacuum-assisted closure ”and“ topical negative pressure ”, for example. Negative pressure therapy can provide several benefits, including migration of epithelial and subcutaneous tissues, improved blood flow and microdeformation of the tissue at a wound site. Together, these benefits can increase the development of granulation tissue and reduce the healing time.
[0004] [0004] There is also widespread acceptance that cleaning a tissue site can be highly beneficial for new tissue growth. For example, a wound or cavity can be washed with a liquid solution for therapeutic purposes. These practices are commonly called “irrigation” and “washing”, respectively. “Instillation” is another practice that generally refers to a process of slowly introducing the fluid into a tissue site and maintaining the fluid for a prescribed period of time before removing the fluid. For example, the instillation of topical treatment solutions onto a wound bed can be combined with negative pressure therapy to further promote wound healing, by loosening soluble contaminants in a wound bed and removing the infectious material. As a result, the soluble bacterial load can be decreased, contaminants removed and the wound cleaned.
[0005] [0005] While the clinical benefits of negative pressure therapy and / or instillation therapy are widely known, improvements in therapy systems, components and processes can benefit healthcare professionals and patients. BRIEF SUMMARY
[0006] [0006] New and useful systems, apparatus and methods for treating tissue in a negative pressure therapy environment are presented in the appended claims. Illustrative modalities are also provided to enable an individual skilled in the art to produce and use the claimed material.
[0007] [0007] For example, in some embodiments, a dressing to treat fabric may be a composite of dressing layers, including a sealing layer, a fluid control layer, a transmitter and a cover. In some examples, the sealing layer may comprise or consist essentially of a layer of perforated gel, such as a silicone gel. A central area of the gel can be removed to define an opening for treatment. The fluid control layer may comprise or consist essentially of a polyurethane film that has fluid restrictions, such as fenestrations in the film. The film can be supported with an acrylic adhesive in some modalities. The transmitter can be a crosslinked foam in some examples, and the polyurethane film can be laminated to the transmitter or the acrylic adhesive on the polyurethane film can join the two. In some instances, the polyurethane film can be laminated to the transmitter and then cut to a desired size and shape, which can simplify manufacturing processes.
[0008] [0008] In some examples, the transmitter and the fluid control layer may have a diameter that is larger than the treatment opening, so that the edge of the transmitter is not exposed when mounted and applied to a tissue site. The fluid control layer can be arranged over the treatment opening so that a substantial number of fluid restrictions are aligned with the treatment opening. For example, the transmitter and the fluid control layer can be substantially aligned with the treatment opening, although a wide tolerance may be acceptable. The transmitter and the fluid control layer can overlap an area of the sealing layer around the treatment opening, and the sealing layer can have an adhesive in the overlap area to secure the transmitter, the fluid control layer , or both. The cover can be positioned over the mounted transmitter and the fluid control layer and adhered to the sealing layer to enclose the transmitter.
[0009] [0009] In some embodiments, the sealing layer may comprise or consist essentially of a layer of perforated gel, such as a silicone gel, which has perforations distributed continuously through the sealing layer. Fluid restrictions in the fluid control layer can be arranged within the perforations, which can provide functionality similar to the treatment opening while increasing the surface area of the sealing layer.
[0010] [0010] More generally, a dressing to treat a fabric site with negative pressure may comprise a sealing layer that has a treatment opening and a plurality of perforations around the treatment opening, and a fluid control layer that has a plurality of fluid restrictions aligned with the treatment opening. A transmitter can be disposed adjacent to fluid restrictions, and a cover comprising a non-porous film can be disposed on the transmitter and coupled to the sealing layer around the transmitter. The cover may additionally have a pressure sensitive adhesive disposed adjacent to the plurality of perforations. In more particular embodiments, the fluid control layer may comprise or consist essentially of a polyurethane film. The sealing layer can be formed from a gel, like a silicone gel in some embodiments.
[0011] [0011] In some examples, the transmitter may have a first edge that defines a transmitter face adjacent to the fluid control layer, and the fluid control layer may have a second edge that defines a fluid control face adjacent to the fluid control layer. transmitter face. The fluid control face and the transmitter face may be similarly shaped in some embodiments. The transmitter face can be at least as large as the fluid control face, and the fluid control face can be larger than the treatment opening. In more specific examples, at least one of the transmitter and the fluid control layer can be coupled to a margin around the treatment opening.
[0012] Alternatively, other exemplary embodiments of a dressing for treating a negative pressure tissue site may comprise a transmitter and a fluid control layer comprising a plurality of fluid constraints adjacent to the transmitter. A sealing layer comprising a plurality of perforations can be arranged adjacent to the fluid control layer and at least some of the perforations can be aligned with more than one of the fluid constraints. A cover comprising a non-porous film can be disposed on the transmitter and coupled to the sealing layer around the transmitter. The cover may additionally have a pressure sensitive adhesive disposed adjacent to the plurality of perforations. In more particular embodiments, the fluid control layer may comprise or consist essentially of a polyurethane film. The sealing layer can be formed from a gel, like a silicone gel in some embodiments.
[0013] [0013] In more particular examples, fluid restrictions may comprise cracks, which can be from about 2 millimeters to about 5 millimeters in length. The perforations in the sealing layer can be circular, having a diameter large enough to align with more than one fluid restriction. For example, a diameter in the range of about 7 millimeters to about 9 millimeters may be suitable for some configurations.
[0014] [0014] In some embodiments, a dressing to treat a tissue site with negative pressure may comprise a cover that has an adhesive, a transmitter, a perforated polymer film and a perforated silicone gel that has an opening for treatment. The cover, transmitter, perforated polymer film and perforated silicone gel can be mounted in a stacked relationship with the cover and perforated silicone gel by closing the transmitter. The perforated polymer film can be at least partially exposed through the treatment opening, and at least part of the adhesive can be exposed through the perforated silicone around the treatment opening.
[0015] [0015] A dressing to treat a tissue site with negative pressure may comprise a transmitter, a gel layer, a fluid control layer and a cover in some embodiments. The gel layer may comprise an open central window and a plurality of openings around the open central window. The fluid control layer can extend through the open central window and comprise a plurality of fluid restrictions. The cover can comprise a non-porous film and a pressure sensitive adhesive, and the non-porous film can be placed on the transmitter and coupled to the gel layer around the transmitter, and the pressure sensitive adhesive can be disposed adjacent to the plurality of perforations.
[0016] [0016] In some embodiments, a dressing to treat a tissue site with negative pressure may comprise a foam transmitter for the passage of negative pressure and the passage of wound fluid; a lower surface that has an open area for distributing negative pressure and passing wound fluid through the transmitter, where the open area is surrounded by a surgical field area for sealing the tissue, the surgical field area has an adhesive and does not include openings for the passage of negative pressure through the transmitter; and a wound contact layer of polymer film that extends through the open area on the bottom surface and has openings for the passage of negative pressure and wound fluid in the foam transmitter. The dressing may also comprise a cover in some embodiments, in which the cover comprises a surgical field arranged over the transmitter and coupled to the surgical field area around the transmitter.
[0017] [0017] Objectives, advantages and a preferential way to produce and use the claimed material can be better understood by referring to the attached drawings together with the detailed description below of the illustrative modalities. BRIEF DESCRIPTION OF THE DRAWINGS
[0018] [0018] Figure 1 is a functional block diagram of an exemplary modality of a therapy system that can provide negative pressure treatment and instillation treatment according to this specification;
[0019] [0019] Figure 2 is an assembly view of an example of a dressing, which illustrates additional details that can be associated with some exemplary modalities of the therapy system of Figure 1;
[0020] [0020] Figure 3 is a top view of the exemplary dressing in Figure 2;
[0021] [0021] Figure 4 is a bottom view of the exemplary dressing in Figure 2;
[0022] [0022] Figure 5 is an assembly view of another example of a dressing, which illustrates additional details that can be associated with some exemplary embodiment of the therapy system of Figure 1;
[0023] [0023] Figure 6 is a schematic view of an exemplary configuration of fluid restrictions in a layer that can be associated with some embodiments of the dressing of Figure 2 or Figure 5;
[0024] [0024] Figure 7 is a schematic view of an exemplary configuration of openings in a layer that can be associated with some modalities of the dressing of Figure 5; and
[0025] [0025] Figure 8 is a schematic view of the example layer of Figure 6 superimposed on the example layer of Figure 7. DESCRIPTION OF EXEMPLIFICATIVE MODALITIES
[0026] [0026] The following description of the exemplary modalities provides information that enables an individual skilled in the art to produce and use the material presented in the attached claims, but may omit certain details already well known in the art. The following detailed description should therefore be considered illustrative and not limiting.
[0027] [0027] The exemplary modalities can also be described in this document with reference to the spatial relationships between various elements or the spatial orientation of various elements represented in the attached drawings. In general, such relationships or guidance assume consistent or relative reference support to a patient in a position to receive treatment. However, as should be recognized by those skilled in the art, this reference support is merely a descriptive expedient, rather than a strict prescription.
[0028] [0028] Figure 1 is a simplified functional block diagram of an exemplary embodiment of a therapy system 100 that can deliver negative pressure therapy with instillation of topical treatment solutions to a tissue site according to this specification.
[0029] [0029] The term "tissue site", in this context, refers broadly to an injury, defect or other treatment target located in or within the tissue, including, but not limited to, bone tissue, adipose tissue, muscle tissue , neural tissue, dermal tissue, vascular tissue, connective tissue, cartilage, tendons or ligaments. An injury can include chronic, acute, traumatic, subacute and dehiscent wounds, partial thickness burns, ulcers (such as diabetic, pressure or venous insufficiency), flaps and grafts, for example. The term "tissue site" can also refer to areas of any tissue that are not necessarily injured or defective, but are instead areas in which it may be desirable to add or promote additional tissue growth. For example, negative pressure can be applied to a tissue site to grow additional tissue that can be harvested and transplanted.
[0030] [0030] Therapy system 100 may include a negative pressure source or supply, such as a negative pressure source 105, and one or more delivery components. A distribution component is preferably removable and can be disposable, reusable or recyclable. A dressing, like a dressing 110, and a fluid container, like a container 115, are examples of delivery components that can be associated with some examples of therapy system 100. As illustrated in the example in Figure 1, the dressing
[0031] [0031] A fluid conductor is another illustrative example of a distribution component. A "fluid conductor," in this context, broadly includes a tube, pipe, hose, conduit, or other structure with one or more lumens or open paths adapted to transport a fluid between two ends. Typically, a tube is an elongated cylindrical structure with some flexibility, but the geometry and stiffness can vary. In addition, some fluid conductors can be molded or otherwise integrally combined with other components. Distribution components can also include or comprise interfaces or fluid ports to facilitate coupling and decoupling other components. In some embodiments, for example, a dressing interface can facilitate coupling a fluid conductor to dressing 110. For example, such a dressing interface may be a SENSAT.RAC ™ Block available from Kinetic Concepts, Inc. of San Antonio, Texas.
[0032] [0032] Therapy system 100 may also include a regulator or controller, such as a controller 130. Additionally, therapy system 100 may include sensors for measuring operational parameters and providing feedback signals to controller 130 indicative of operating parameters. As illustrated in Figure 1, for example, therapy system 100 can include a first sensor 135 and a second sensor 140 coupled to controller 130.
[0033] [0033] Therapy system 100 may also include an installation solution source. For example, a source of solution 145 can be fluidly coupled to dressing 110, as illustrated in the exemplary embodiment of Figure 1. The source of solution 145 can be fluidly coupled to a positive pressure source, such as a pressure source. positive 150, a negative pressure source, such as negative pressure source 105, or both in some embodiments. A regulator, such as installation regulator 155, can also be fluidly coupled to solution source 145 and dressing 110 to ensure proper dosing of installation solution (e.g., saline) to a tissue site. For example, installation regulator 155 may comprise a piston that can be pneumatically actuated by the negative pressure source 105 to extract installation solution from the solution source during a negative pressure interval and instill the solution into a dressing during a ventilation interval . In addition or alternatively, the controller 130 can be coupled to the negative pressure source 105, positive pressure source 150, or both, to control the dosage of installation solution to a tissue site. In some embodiments, installation regulator 155 can also be fluidly coupled to the negative pressure source 105 via dressing 110, as shown in the example in Figure 1.
[0034] [0034] Some components of the therapy system 100 can be housed inside or used in combination with other components, such as sensors, processing units, alarm indicators, memory, databases, software, display devices, or user interfaces that further facilitate therapy. For example, in some embodiments, the negative pressure source 105 can be combined with controller 130, solution source 145, and other components in a therapy unit.
[0035] [0035] In general, the components of the therapy system 100 can be coupled directly or indirectly. For example, the negative pressure source 105 can be directly coupled to container 115 and can be indirectly coupled to dressing 110 through container 115. The coupling can include fluid, mechanical, thermal, electrical or chemical coupling (such as a chemical bond) , or some combination of couplings in some contexts. For example, the negative pressure source 105 can be electrically coupled to controller 130 and can be fluidly coupled to one or more delivery components to provide a fluid path to a tissue site. In some embodiments, the components can also be coupled due to physical proximity, being an integral part of a single structure or formed from the same piece of material.
[0036] [0036] A negative pressure supply, such as the negative pressure source 105, can be a negative pressure air reservoir or it can be a manual or electrically powered device, such as a vacuum pump, a suction pump, a suction port to the wall available in many health care facilities or a micro pump, for example. "Negative pressure" generally refers to a pressure less than a local ambient pressure, such as ambient pressure in a local environment outside a sealed therapeutic environment. In many cases, the local ambient pressure can also be the atmospheric pressure at which a tissue site is located. Alternatively, the pressure may be less than a hydrostatic pressure associated with the tissue at the tissue site. Unless otherwise stated, the pressure values mentioned in this document are effective pressures. negative pressure typically refer to a decrease in absolute pressure, while decreases in negative pressure typically refer to an increase in absolute pressure, although the amount and nature of negative pressure provided by the negative pressure source 105 may vary according to therapeutic requirements, the pressure is generally a low vacuum, also commonly called a raw vacuum, between -5 mm Hg (-667 Pa) and -500 mm
[0037] [0037] Container 115 is representative of a container, ampoule, pouch or other storage component that can be used to manage exudates and other fluids extracted from a tissue site. In many environments, a rigid container may be preferred or necessary for the collection, storage and disposal of fluids. In other environments, fluids can be properly disposed of without storing the rigid container, and a reusable container could reduce the waste and costs associated with negative pressure therapy.
[0038] [0038] A controller, such as controller 130, may be a microprocessor or computer programmed to operate one or more components of the therapy system 100, such as the negative pressure source 105. In some embodiments, for example, controller 130 may be a microcontroller that generally comprises an integrated circuit containing a processor core and a memory programmed to directly or indirectly control one or more operating parameters of the therapy system 100. Operating parameters may include the power applied to the negative pressure source 105, the pressure generated by the negative pressure source 105 or the pressure distributed to the tissue interface 120, for example. Controller 130 is preferably also configured to receive one or more input signals, such as a feedback signal, and programmed to modify one or more operating parameters based on the input signals.
[0039] [0039] Sensors, such as the first sensor 135 and the second sensor 140, are generally known in the art as any operable device to detect or measure a phenomenon or physical property and generally provide a signal indicative of the phenomenon or property that is detected or measured. For example, the first sensor 135 and the second sensor 140 can be configured to measure one or more operating parameters of the therapy system 100. In some embodiments, the first sensor 135 can be a transducer configured to measure pressure in a pneumatic path and convert the measurement into a signal indicating the measured pressure. In some embodiments, for example, the first sensor 135 may be a piezoresistive stretch gauge. The second sensor 140 can optionally measure operating parameters of the negative pressure source 105, such as a voltage or current, in some embodiments. Preferably, the signals from the first sensor 135 and the second sensor 140 are suitable as an input signal to the controller 130, but some signal conditioning may be appropriate in some embodiments. For example, the signal may need to be filtered or amplified before it can be processed by controller 130. Typically, the signal is an electrical signal, but it can be represented in other forms, as an optical signal.
[0040] [0040] The tissue interface 120 can generally be adapted to come into partial or complete contact with a tissue site. The fabric interface 120 can take many forms, and can have many sizes, shapes, or thicknesses, depending on a variety of factors, such as the type of treatment that is implemented or the nature and size of a fabric site. For example, the size and shape of the fabric interface 120 can be adapted to the contours of deep and irregularly shaped fabric sites. Any or all of the surfaces of the fabric interface 120 can have an irregular, coarse or serrated profile.
[0041] [0041] In some embodiments, the fabric interface 120 may comprise or consist essentially of a transmitter. A transmitter, in this context, may comprise or consist essentially of a means for collecting or distributing fluid through the tissue interface 120 under pressure. For example, a transmitter can be adapted to receive negative pressure from a source and distribute negative pressure through multiple openings through the tissue interface 120, which can have the effect of collecting fluid from a tissue site and dragging the fluid towards the source. In some embodiments, the fluid path may be reversed or a secondary fluid path may be provided to facilitate distribution of fluid, such as fluid from an installation solution source, through a tissue site.
[0042] [0042] In some embodiments, cover 125 can provide a bacterial barrier and protection against physical trauma. The cover 125 can also be constructed from a material that can reduce evaporative losses and provide a fluid seal between two components or two environments, such as between a therapeutic environment and an external site environment. The cover 125 may comprise or consist of, for example, an elastomeric film or membrane that can provide an adequate seal to maintain a negative pressure at a tissue site for a given source of negative pressure. Cover 125 may have a high vapor transmission and humidification rate (MVTR) in some applications. For example, MVTR can be at least 250 grams per square meter for twenty-four hours in some modalities, measured using a vertical cup technique in accordance with ASTM E96 / E96M Vertical Cup Technique at 38 ° C and 10 % relative humidity (RH). In some embodiments, an MVTR of up to 5,000 grams per square meter for twenty-four hours can provide breathability and effective mechanical properties.
[0043] [0043] In some exemplary embodiments, cover 125 may be a surgical field or non-porous polymer film, such as a polyurethane film, which is permeable to water vapor but impermeable to liquid. Such surgical drapes typically have a thickness in the range of 25 to 50 microns. For permeable materials, the permeability should generally be low enough that a desired negative pressure can be maintained. The cover 125 may comprise, for example, one or more of the following materials: polyurethane (PU), such as hydrophilic polyurethane; cellulosic; hydrophilic polyamides; polyvinyl alcohol; polyvinyl pyrrolidone; hydrophilic acrylics; silicones, such as hydrophilic silicone elastomers; natural rubbers; polyisoprene; styrene butadiene rubber; chloroprene rubber; polybutadiene; nitrile rubber; butyl rubber; ethylene propylene rubber; ethylene propylene diene monomer; chlorosulfonated polyethylene; polysulfide rubber; ethylene vinyl acetate (EVA); copolyester; and polyether block copolymers. Such materials are commercially available, for example, the Tegaderm® surgical field, commercially available from 3M Company, Minneapolis Minnesota; polyurethane (PU) surgical field, commercially available from Avery Dennison Corporation, Pasadena, California; polyether block polyamide copolymer (PEBAX), for example, with Arkema S.A., Colombes, France; and Inspire 2301 and Inpsire 2327 polyurethane films, commercially available from Expopack Advanced Coatings, Wrexham, UK. In some embodiments, cover 125 may comprise INSPIRE 2301 which has an MVTR (vertical cup technique) of 2,600 g / m2 / 24 hours and a thickness of about 30 microns.
[0044] [0044] A fixing device can be used to fix the cover 125 to a fixing surface, such as undamaged skin, a gasket or another cover. The fixing device can take any shape. For example, a fixture may be the medically acceptable pressure sensitive adhesive configured to attach the cover 125 to the epidermis around a tissue site. In some embodiments, for example, part or all of the covering 125 may be coated with an adhesive, such as an acrylic adhesive, which may have a coating weight of about 25 to 65 grams per square meter (g.s.m.). Thicker adhesives, or combinations of adhesives, can be applied in some modalities to improve the seal and reduce leaks. Other exemplary embodiments of a fixture may include a double-sided tape, paste, hydrocolloid, hydrogel, silicone gel or organogel.
[0045] [0045] Solution source 145 may also be representative of a container, ampoule, purse, bag, or other storage component, which may provide a solution for instillation therapy. Solution compositions may vary according to a prescribed therapy, but examples of solutions that may be suitable for some prescriptions include hypochlorite-based solutions, silver nitrate (0.5%), sulfur-based solutions, biguanides, solutions cationic and isotonic solutions.
[0046] [0046] In operation, the fabric interface 120 can be placed inside, on, in or otherwise close to a fabric site. If the tissue site is a wound, for example, the tissue interface 120 can partially or completely fill the wound, or it can be placed over the wound. The cover 125 can be placed over the fabric interface 120 and sealed to a fastening surface next to a fabric site. For example, cover 125 can be sealed to undamaged epidermis peripheral to a tissue site. In this way, the dressing 110 can provide a sealed therapeutic environment close to a tissue site, substantially isolated from the external environment, and the negative pressure source 105 can reduce the pressure in the sealed therapeutic environment.
[0047] [0047] Fluid mechanics for using a negative pressure source to reduce pressure in another component or location, such as within a sealed therapeutic environment, can be mathematically complex. However, the basic principles of fluid mechanics applicable to negative pressure therapy and instillation are generally well known to those skilled in the art, and the process for reducing pressure can be described illustratively in this document as "distribution", "distribute" or "generate" negative pressure, for example.
[0048] [0048] In general, the extrudate and other fluid flow towards the lower pressure along a fluid path. Thus, the term "downstream" typically implies something in a fluid path relatively closer to a source of negative pressure or more distant from a source of positive pressure. In contrast, the term "upstream" implies something relatively more distant from a source of negative pressure or closer to a source of positive pressure. Similarly, it may be convenient to describe certain features in terms of "inlet" or "outlet" of fluid in such a reference support. guidance for purposes of describing various features and components in this document, however, the fluid path can also be reversed in some applications, such as replacing a source of positive pressure with a source of negative pressure, and this descriptive convention should not be interpreted as a limiting convention.
[0049] [0049] The negative pressure applied by the tissue site through the tissue interface 120 in the sealed therapeutic environment can induce macrofilament and microfilament at the tissue site. Negative pressure can also remove extrudates and other fluid from a tissue site, which can be collected in container 115.
[0050] [0050] In some embodiments, controller 130 can receive and process data from one or more sensors, such as the first sensor 135. Controller 130 can also control the operation of one or more components of the therapy system 100 to manage distributed pressure for the fabric interface
[0051] [0051] In some embodiments, the controller 130 may have a continuous pressure mode, in which the negative pressure source 105 is operated to provide a constant negative target pressure for the duration of treatment or until manually deactivated. Additionally or alternatively, the controller may have an intermittent pressure mode. For example, controller 130 can operate the negative pressure source 105 to cycle between target pressure and atmospheric pressure. For example, the target pressure can be set to a value of 135 mmHg for a specified period of time (for example, 5 min), followed by a specified period of time (for example, 2 min) for deactivation. The cycle can be repeated by activating the negative pressure source 105, which can form a square wave pattern between the target pressure and atmospheric pressure.
[0052] [0052] In some exemplary embodiments, the increase in negative pressure from ambient pressure to the target pressure may not be instantaneous. For example, the negative pressure source 105 and dressing 110 may have an initial lift time. The initial lift time may vary depending on the type of dressing and the therapy equipment to be used. For example, the initial lift time for one therapy system can be in the range of about 20 to 30 mmHg / second and in the range of about 5 to 10 mmHg / second for another therapy system. If the therapy system 100 is operating in an intermittent mode, the repeat lift time can be a value substantially equal to the initial lift time.
[0053] [0053] In exemplary dynamic pressure control modes, the target pressure can vary over time. For example, the target pressure can vary in the form of a triangular waveform, ranging from a negative pressure of 50 to 135 mmHg with an elevation time defined at a rate of +25 mmHg / min. and a decreasing time defined at -25 mmHg / min. In other modalities of the therapy system 100, the triangular waveform can vary between negative pressure of 25 and 135 mmHg with an elevation time set at a rate of +30 mmHg / min and a decreasing time set at -30 mmHg / min .
[0054] [0054] In some embodiments, controller 130 can control or determine a variable target pressure in a dynamic pressure mode, and the variable target pressure can vary between a maximum and minimum pressure value that can be defined as an input prescribed by a operator as the desired negative pressure range. The variable target pressure can also be processed and controlled by controller 130, which can vary the target pressure according to a predetermined waveform, such as a triangular waveform, a sine waveform or a serrated waveform. In some embodiments, the waveform can be defined by an operator as the predetermined or variable time pressure desired for therapy.
[0055] [0055] In some embodiments, controller 130 can receive and process data, such as data related to the installation solution provided for the fabric interface
[0056] [0056] Controller 130 can also control instillation fluid dynamics by providing a continuous flow of solution or an intermittent flow of solution. Negative pressure can be applied to provide either continuous flow or intermittent flow of solution. The application of negative pressure can be implemented to provide a continuous operating pressure mode to achieve a continuous flow rate of installation solution through the fabric interface 120, or it can be implemented to provide a dynamic operating pressure mode to vary the flow rate of installation solution through the fabric interface
[0057] [0057] Figure 2 is an assembly view of an example of the dressing 110 of Figure 1 that illustrates additional details that can be associated with some embodiments in which the fabric interface 120 comprises more than one layer. In the example of Figure 2, the fabric interface 120 comprises a first layer 205, a second layer 210 and a third layer 215. In some embodiments, the first layer 205 can be arranged adjacent to the second layer 210, and the third layer 215 also it can be arranged adjacent to the second layer 210 opposite the first layer 205. For example, the first layer 205 and the second layer 210 can be stacked so that the first layer 205 is in contact with the second layer
[0058] [0058] The first layer 205 generally comprises or consists essentially of a transmitter or a transmitting layer, which provides a means for collecting or distributing fluid through the tissue interface 120 under pressure. For example, the first layer 205 can be adapted to receive negative pressure from a source and distribute the negative pressure through multiple openings through the tissue interface 120, which can have the effect of collecting fluid from a tissue site and dragging the fluid towards the source. In some embodiments, the fluid path can be reversed or a secondary fluid path can be provided to facilitate fluid distribution, such as from an instillation solution source, through the tissue interface 120.
[0059] [0059] In some illustrative modalities, the trajectories of the first layer 205 can be interconnected to improve distribution or collection of fluids. In some illustrative embodiments, the first layer 205 may comprise or consist essentially of a porous material that has interconnected fluid paths. Examples of suitable porous material that comprises or can be adapted to form interconnected fluid paths (e.g., channels) can include cellular foam, including open cell foam such as cross-linked foam; porous tissue collections; and other porous material such as gauze or felt carpet that generally includes pores, edges and / or walls. Liquids, gels and other foams can also include or be cured to include fluid openings and trajectories. In some embodiments, the first layer 205 may, additionally or alternatively, comprise projections that form interconnected fluid paths. For example, the first layer 205 can be shaped to provide surface projections that define interconnected fluid paths.
[0060] [0060] In some embodiments, the first layer 205 may comprise or consist essentially of a cross-linked foam that has pore sizes and free volume that may vary according to the needs of a prescribed therapy. For example, a cross-linked foam that has a free volume of at least 90% may be suitable for many therapy applications, and foam that has an average pore size in the range of 400 to 600 microns may be particularly suitable for some types of therapy. The tensile strength of the first layer 205 may also vary according to the needs of a prescribed therapy. For example, the tensile strength of a foam can be increased to instill topical treatment solutions. The 25% compression load deflection of the first layer 205 can be at least 0.025 kilograms per square centimeter (0.35 pounds per square inch), and the 65% compression load deflection can be at least 0.030 kilograms per square centimeter (0.43 pounds per square inch). In some embodiments, the tensile strength of the first layer 205 may be at least 0.7 kilograms per square centimeter (10 pounds per square inch). The first layer 205 can have a tensile strength of at least 0.45 kilogram per centimeter (2.5 pounds per inch). In some embodiments, the first layer 205 may be a foam comprised of polyols, such as polyester or polyether, isocyanate, such as toluene diisocyanate, and polymerization modifiers, such as amines and tin compounds. In some examples, the first layer 205 may be a cross-linked polyurethane foam as used in GRANUFOAM ™ or V.A.C. I think VERAFLO ™, both available from KCI in San Antonio, Texas.
[0061] [0061] Other materials suitable for the first layer 205 may include non-woven cloths (Libeltex, Freudenberg), three-dimensional (3D) polymeric structures (molded polymers, formed and etched films, and melt-linked films [Supracore]), and mesh, for example.
[0062] [0062] In some examples, the first layer 205 may include a 3D textile, such as several textiles commercially available from Baltex, Muller and Heathcoates. A 3D textile made of polyester fibers can be particularly advantageous for some modalities. For example, the first layer 205 may comprise or consist essentially of a three-dimensional wave of polyester fibers. In some embodiments, the fibers may be elastic in at least two dimensions. A puncture-resistant cloth made of polyester and cotton fibers that weighs about 650 grams per square meter and has a thickness of about 1 to 2 millimeters can be particularly advantageous for some modalities. Such a puncture-resistant cloth may have a tensile strength by distortion of about 330 to 340 kilograms and a tensile strength by weave of around 270 to 280 kilograms in some embodiments. Another particularly suitable material may be a polyester spacer cloth that has a weight of about 470 grams per square meter, which can have a thickness of about 4 to 5 millimeters in some embodiments. Such a spacer cloth can have a compressive strength of about 20 to 25 kilo pascals (at 40% compression). In addition or alternatively, the first layer 205 can comprise or consist of a material that has substantial linear stretching properties, such as a polyester spacer cloth that has bidirectional stretching and a weight of about 380 grams per square meter. A suitable spacer cloth can have a thickness of about 3 to 4 millimeters, and can have a tensile strength by warp or distortion of around 30 to 40 kilograms in some embodiments. The cloth may have a layer of closed polyester fabric on one or more opposite faces in some examples. In some embodiments, a layer of fabric may advantageously be arranged on a first layer 205 to face a fabric site.
[0063] [0063] The first layer 205 generally has a first flat surface and a second flat surface opposite the first flat surface. The thickness of the first layer 205 between the first flat surface and the second flat surface can also vary according to the needs of a prescribed therapy. For example, the thickness of the first layer 205 can be decreased to relieve stress on other layers and to reduce tension in the peripheral tissue. The thickness of the first layer 205 can also affect the formability of the first layer 205. In some embodiments, a suitable foam can have a thickness in a range of about 5 millimeters to 10 millimeters. Cloths, including suitable 3D textiles and spacer cloths, can have a thickness in a range of about 2mm to about 8mm.
[0064] [0064] The second layer 210 may comprise or consist essentially of a means to control or manage the flow of fluid. In some embodiments, the second layer 210 may be a fluid control layer comprising or consisting essentially of an elastomeric material, impermeable to liquid. For example, the second layer 210 may comprise or consist essentially of a polymer film, such as a polyurethane film. In some embodiments, the second layer 210 may comprise or consist essentially of the same material as the cover 125. The second layer 210 may also have a smooth or matte surface texture in some embodiments. A satin or glossy finish better than or equal to a B3 grade according to SPI (Plastic Industry Society) standards can be particularly advantageous for some applications. In some embodiments, variations in the height of the surface may be limited to acceptable tolerances. For example, the surface of the second layer 210 may have a substantially flat surface, with height variations limited to 0.2 millimeters in one centimeter.
[0065] [0065] In some embodiments, the second layer 210 may be hydrophobic. The hydrophobicity of the second layer 210 may vary, but may have an angle of contact with water of at least ninety degrees in some embodiments. In some embodiments, the second layer 210 can have a contact angle with water of a maximum of 150 degrees. For example, in some embodiments, the contact angle of the second layer 210 may be in a range of at least 90 degrees to about 120 degrees or in a range of at least 120 degrees to 150 degrees. The angles of contact with water can be measured using any standard device. Although manual goniometers can be used to visually approximate contact angles, contact angle measurement instruments can often include an integrated system that involves a level stage, a liquid dropper, such as a syringe, camera and software designed to calculate contact angles with more accuracy and precision, among other things. Non-limiting examples of such integrated systems may include the FTÅ125, FTÅ200, FTÅ2000 and FTÅ4000 systems, all commercially available from First Ten Angstroms, Inc., Portsmouth, VA, and the DTA25, DTA30 and DTA100 systems, all commercially available from Kruss GmbH from Hamburg, Germany. Unless otherwise specified, the angles of contact with water in this document are measured using deionized and distilled water on a level sample surface for a sessile drop added from a maximum height of 5 cm in the air at 20 to 25 ° C and 20 to 50% relative humidity. The contact angles in this document represent averages of 5 to 9 measured values, discarding the highest and lowest measured values. The hydrophobicity of the second layer 210 can be further enhanced with a hydrophobic coating of other materials, such as silicones and fluorocarbons, whether coated with a liquid or coated with plasma.
[0066] [0066] The second layer 210 can also be suitable for welding to other layers, including the first layer 205. For example, the second layer 210 can be adapted for welding to polyurethane foams using heat, radiofrequency (RF) welding ) or other methods to generate heat, such as ultrasonic welding. RF welding can be particularly suitable for more polar materials, such as polyurethane, polyamides, polyesters and acrylates. Polar sacrificial interfaces can be used to facilitate RF welding of less polar film materials, such as polyethylene.
[0067] [0067] The area density of the second layer 210 may vary according to a prescribed therapy or application. In some embodiments, an area density of less than 40 grams per square meter may be suitable, and an area density of about 20 to 30 grams per square meter may be particularly advantageous for some applications.
[0068] [0068] In some embodiments, for example, the second layer 210 may comprise or consist essentially of a hydrophobic polymer, such as a polyethylene film. The simple and inert structure of polyethylene can provide a surface that interacts little, if at all, with biological tissues and fluids, providing a surface that can encourage free flow of liquids and low adhesion, which can be particularly advantageous for many applications. Other suitable polymeric films include polyurethanes, acrylics, polyolefin (such as cyclic olefin copolymers), polyacetates, polyamides, polyesters, copolyesters, PEBAX block copolymers, thermoplastic elastomers, thermoplastic vulcanized, polyethers, polyvinyl alcohol, polypropylene, polypropylene, polypropylene polyethylene, polypropylene, polypropylene, polypropylene, polypropylene. , silicones, fluoropolymers and acetates. A thickness between 20 microns and 100 microns can be suitable for many applications. Films can be transparent, colored or printed. More polar films suitable for lamination to a polyethylene film include polyamide, copolyesters, ionomers and acrylics. To aid in the connection between a polyethylene and polar film, display layers can be used, such as ethylene vinyl acetate or modified polyurethanes. An ethyl methyl acrylate (EMA) film may also have suitable hydrophobic and welding properties for some configurations.
[0069] [0069] As illustrated in the example of Figure 2, the second layer 210 can have one or more fluid restrictions 220 that can be distributed evenly and randomly through the second layer 210. Fluid restrictions 220 can be bidirectional and pressure responsive. For example, each of the fluid restrictions 220 can generally comprise or consist essentially of an elastic passageway that is not normally stretched to substantially reduce the flow of liquid and may expand or open in response to a pressure gradient. In some embodiments, fluid restrictions 220 may comprise or consist essentially of perforations in the second layer 210. Perforations can be formed by removing material from the second layer 210. For example, perforations can be formed by cutting through the second layer 210, which can also deform the perforation edges in some modalities. In the absence of a pressure gradient through the perforations, the passages may be small enough to form a seal or fluid restriction, which can substantially reduce or impede the flow of liquid. Additionally or alternatively, one or more of the fluid restrictions 220 may be an elastomeric valve that is normally closed when not stretched to substantially prevent the flow of liquid and may open in response to a pressure gradient. A fenestration in the second layer 210 can be a suitable valve for some applications. Fenestrations can also be formed by removing the material from the second layer 210, but the amount of material removed and the dimensions resulting from the fenestrations can be up to an order of magnitude less than the perforations and may not deform the edges.
[0070] [0070] For example, some modalities of fluid restrictions 220 may comprise or consist essentially of one or more slits, notches or combinations of slits and notches in the second layer 210. In some examples, fluid restrictions 220 may comprise or consist of linear notches that are less than 4 millimeters long and less than 1 millimeters wide. The length can be at least 2 millimeters, and the width can be at least
[0071] [0071] The third layer 215 may comprise or consist essentially of a sealing layer formed from a soft malleable material suitable to provide a fluid seal with a fabric site, such as a suitable gel material, and may have a surface substantially flat. For example, third layer 215 may comprise, without limitation, a silicone gel, a soft silicone, hydrocolloid, hydrogel, polyurethane gel, polyolefin gel, hydrogenated styrenic copolymer gel, a foamed gel, a soft cell foam closed, such as polyurethanes and polyolefins coated with an adhesive, polyurethane, polyolefin or copolymers of hydrogenated styrenics. In some embodiments, the third layer 215 can have a thickness between about 200 microns (μm) and about 1,000 microns (μm). In some embodiments, the third layer 215 may have a hardness between about 5 Shore OO and about 80 Shore OO. In addition, the third layer 215 may be comprised of hydrophobic or hydrophilic materials.
[0072] [0072] In some embodiments, the third layer 215 may be a material coated with a hydrophobic product. For example, the third layer 215 can be formed by coating a spaced material, such as, for example, woven, nonwoven, molded or extruded with a hydrophobic material. The hydrophobic material for the coating can be a soft silicone, for example.
[0073] [0073] The third layer 215 can have a periphery 225 surrounding or around a treatment opening 230, and openings 235 in the periphery 225 arranged around the treatment opening 230. The treatment opening 230 can be complementary or correspond to a surface area of the first layer 205 in some examples. For example, the treatment opening 230 can form a support, window, or other opening around a surface of the first layer 205. The third layer 215 can also have corners 240 and edges 245. Corners 240 and edges 245 can make part of the periphery 225. The third layer 215 may have an inner margin 250 around the treatment opening 230, which can be substantially free from the openings 235, as shown in the example in Figure 2. In some examples, as shown in Figure 2, the treatment opening 230 can be symmetrical and centrally arranged in the third layer 215, forming an open central window.
[0074] [0074] The openings 235 can be formed by cutting, perforating, or by applying local RF or ultrasonic energy, for example, or by other techniques suitable for forming an opening or perforation in the third layer 215. The openings 235 can have a uniform distribution pattern or can be randomly distributed in the third layer 215. The openings 235 in the third layer 215 can have many shapes, including circles, squares, stars, ovals, polygons, slits, complex curves, rectilinear shapes, triangles or may have some combination of such formats.
[0075] [0075] Each of the openings 235 may have uniform or similar geometric properties. For example, in some embodiments, each of the openings 235 may be circular openings having substantially the same diameter. In some embodiments, each of the openings 235 may have a diameter of about 1 millimeter to about 50 millimeters. In other embodiments, the diameter of each of the openings 235 can be from about 1 millimeter to about 20 millimeters.
[0076] [0076] In other embodiments, the geometric properties of the openings 235 may vary. For example, the diameter of the openings 235 can vary depending on the position of the openings 235 in the third layer 215. For example, in some embodiments, the openings 235 arranged on the periphery 225 can have a diameter between about 5 millimeters and about 10 millimeters. A range of about 7 millimeters to about 9 millimeters may be suitable for some examples. In some embodiments, the openings 235 arranged in the corners 240 can have a diameter between about 7 millimeters and about 8 millimeters.
[0077] [0077] At least one of the openings 235 in the periphery 225 of the third layer 215 can be positioned at the edges 245 of the periphery 225 and can have an open or exposed inner cut at the edges 245 which is in fluid communication in a lateral direction with the edges 245 The lateral direction can refer to a direction for the edges 245 and in the same plane as the third layer 215. As shown in the example in Figure 2, the openings 235 in the periphery 225 can be positioned close to the edges 245 or on them and be in fluid communication in a lateral direction with the edges 245. The openings 235 positioned close to the edges 245 or on them can be spaced substantially equidistant around the periphery 225 as shown in the example in Figure 2. Alternatively, the spacing of the openings 235 close to or at the edges 245 may be irregular.
[0078] [0078] As illustrated in the example of Figure 2, the dressing 110 may further include a fixing device, such as an adhesive 255. The adhesive 255 may be, for example, a medically acceptable pressure sensitive adhesive that extends over a periphery, a portion, or an entire roof surface
[0079] [0079] As illustrated in the example of Figure 2, in some embodiments, dressing 110 may include a release liner 260 to protect adhesive 255 prior to use. Release liner 260 can also provide stiffness to assist with, for example, implantation of dressing 110. Release liner 260 can be, for example, a wrapping paper, film or polyethylene. Additionally, in some embodiments, the release liner 260 may be a polyester material,
[0080] [0080] Figure 2 also illustrates an example of a fluid conductor 265 and a dressing interface 270. As shown in the example in Figure 2, fluid conductor 265 can be a flexible tube that can be fluidly coupled in a end to dressing interface 270. Dressing interface 270 can be an elbow connector, as shown in the example in Figure 2, which can be placed over an opening 275 in cover 125 to provide a fluid path between the fluid conductor 265 and the fabric interface
[0081] [0081] One or more of the components of dressing 110 may be additionally treated with an antimicrobial agent in some embodiments. For example, the first layer 205 may be a foam, mesh or nonwoven coated with an antimicrobial agent. In some embodiments, the first layer may comprise antimicrobial elements, such as fibers coated with an antimicrobial agent. In addition or alternatively, some embodiments of the second layer 210 may be a polymer coated or mixed with an antimicrobial agent. In other examples, the fluid conductor 265 can, additionally or alternatively, be treated with one or more antimicrobial agents. Suitable antimicrobial agents can include, for example, metallic silver, PHMB, iodine and their complexes and mixtures, such as povidone iodine, copper metallic compounds, chlorhexidine or some combination of these materials.
[0082] [0082] Additionally or alternatively, one or more of the components can be coated with a mixture that can include citric acid and collagen, which can reduce biofilms and infections. For example, the first layer 205 may be a foam coated with such a mixture.
[0083] [0083] Figure 3 is a top view of dressing 110 in the example of Figure 2, as assembled, which illustrates additional details that can be associated with some embodiments. As illustrated in the example in Figure 2, cover 125 and third layer 215 can have substantially the same shape of perimeter and dimensions, so that cover 125 and third layer 215 are coextensive in some examples. The cover 125 can be substantially transparent, allowing visibility of the openings 235 in some embodiments. The first layer 205 can be centrally arranged over the third layer 215, as well as over the treatment opening 230 (not visible in Figure 3). The cover 125 can be disposed over the first layer 205 and coupled to the third layer 215 around the first layer 205 so that at least part of the adhesive 255 can be disposed adjacent to the openings 235.
[0084] [0084] Figure 4 is a bottom view of dressing 110 in the example of Figure 2, as assembled, which illustrates additional details that can be associated with some embodiments. As illustrated in the example in Figure 4, a substantial number of fluid restrictions 220 can be aligned or otherwise exposed through the treatment opening 230, and at least part of the first layer portion 205 can be arranged adjacent to the flow restrictions. fluid 220 opposite treatment opening 230. In some embodiments, the first layer 205 and the second layer 210 can be substantially aligned with the treatment opening 230, or can extend through the treatment opening 230.
[0085] [0085] In addition, the first layer 205 may have a first edge 405, and the second layer 210 may have a second edge 410. In some instances, the first edge 405 and the second edge 410 may have substantially the same shape so that adjacent faces of the first layer 205 and the second layer 210 are geometrically similar. The first edge 405 and the second edge 410 can also be congruent in some examples, so that adjacent faces of the first layer 205 and the second layer 210 are substantially coextensive and have substantially the same surface area. In the example of Figure 4, the first edge 405 defines a larger face of the first layer 205 than the face of the second layer 210 defined by the second edge 410, and the largest face of the first layer 205 extends after the smallest face of the second edge 410.
[0086] [0086] The faces defined by the first edge 405, the second edge 410 or both can also be geometrically similar to the treatment opening 230 in some modalities, as illustrated in the example of Figure
[0087] [0087] Figure 5 is an assembly view of another example of dressing 110 in Figure 1, which illustrates additional details that can be associated with some embodiments. As illustrated in Figure 5, some examples of the third layer 215 may not have the treatment opening 230, and the openings 235 may be distributed in a uniform pattern across the third layer 215.
[0088] [0088] Figure 6 is a schematic view of an example of the second layer 210, which illustrates additional details that can be associated with some modalities. As illustrated in the example in Figure 6, fluid constraints 220 can each essentially consist of one or more slits having a length L. A length of about 3 millimeters may be particularly suitable for some embodiments. Figure 6 further illustrates an example of a uniform distribution pattern of fluid restrictions 220. In Figure 6, fluid restrictions 220 are substantially coextensive with the second layer 210, and are distributed through the second layer 210 in a grid of rows. and parallel columns, in which the slits are also mutually parallel to each other. In some embodiments, the rows can be spaced at a distance D1. A distance of about 3 millimeters in the center may be suitable for some modalities. Fluid restrictions 220 within each row can be spaced at a distance D2, which may be about 3 millimeters in the center in some instances. Fluid restrictions 220 in adjacent rows can be aligned or shifted in some embodiments. For example, adjacent rows can be moved, as shown in Figure 6, so that fluid restrictions 220 are aligned in alternating rows and separated by a distance D3, which may be about 6 millimeters in some embodiments. The spacing of fluid restrictions 220 may vary in some embodiments to increase the density of fluid restrictions 220 according to therapeutic requirements.
[0089] [0089] Figure 7 is a schematic view of an exemplary configuration of the openings 235, which illustrates additional details that can be associated with some embodiments of the third layer 215. In the example of Figure 7, the openings 420 are generally circular and have a diameter D4, which can be from about 6 millimeters to about 8 millimeters in some modalities. A D4 diameter of about 7 millimeters may be particularly suitable for some modalities. Figure 7 also illustrates an example of a uniform distribution pattern of openings 235. In Figure 7, openings 235 are distributed through the third layer 215 in a grid of parallel rows and columns. In each row and column, the openings 235 can be equidistant from each other, as illustrated in the example in Figure 7. Figure 7 illustrates an exemplary configuration that can be particularly suitable for many applications, where the openings 235 are spaced at a distance D5 separated along each row and column, with an offset of D6. In some instances, the D5 distance can be about 9 millimeters to about 10 millimeters, and the D6 offset can be about 8 millimeters to about 9 millimeters.
[0090] [0090] Figure 8 is a schematic view of the openings 235 in the example of Figure 7 superimposed on the second layer 210 of Figure 6, which illustrates additional details that can be associated with some exemplary modalities of the fabric interface 120. For example, as illustrated in Figure 8, more than one of the fluid restrictions 220 can be aligned, overlapped, leveled, or otherwise, fluidly coupled to the openings 235 in some embodiments. In some embodiments, one or more of the fluid restrictions 220 can only be partially registered with the openings
[0091] [0091] As illustrated in the example in Figure 8, the openings 235 can be sized to expose a portion of the second layer 210, fluid constraints 220 or both through the third layer 215. The openings 235 in the example in Figure 8 are generally sized to expose more than one of the fluid restrictions 220. Some or all of the openings 235 can be sized to expose two or three of the fluid restrictions 220. In some examples, the length of each of the fluid restrictions 220 can be substantially smaller than the diameter of each of the openings
[0092] [0092] The individual components of the dressing 110 in the examples of Figures 2 to 8 can be bonded or otherwise attached to each other with a solvent or non-solvent adhesive, or with thermal welding, for example, without adversely affecting management of fluid. In addition, the second layer 210 or the first layer 205 can be coupled to the inner margin 250 or the overlap margin 415 of the third layer 215 in any suitable manner, such as with a solder or an adhesive, for example.
[0093] [0093] The cover 125, the first layer 205, the second layer 210, the third layer 215 or various combinations can be assembled before application or in situ. For example, the second layer 210 can be laminated to the first layer 205 in some embodiments. The cover 125 can be disposed on the first layer 205 and coupled to the third layer 215 around the first layer 205 in some embodiments. In some embodiments, one or more layers of the fabric interface 120 may be coextensive. For example, the second layer 210 can be cut flush with the edge of the first layer 205. In some embodiments, dressing 110 may be provided as a single composite dressing. For example, the third layer 215 can be coupled to the cover 125 to close the first layer 205 and the second layer 210, where the third layer 215 can be configured to face a fabric site.
[0094] [0094] In use, release liner 260 (if included) can be removed to expose the third layer 215, which can provide a lower dressing surface 110 to be placed inside, over, in or otherwise close to a tissue site, particularly an adjacent surface and epidermis tissue site. The second layer 210, the third layer 215, or both, can be interposed between the first layer 205 and the tissue site, which can substantially reduce or eliminate adverse interaction between the first layer 205 and the tissue site. For example, the third layer 215 can be placed over a superficial wound (including the edges of the wound) and the skin undamaged to prevent direct contact with the first layer 205. In some applications, the treatment opening 230 of the third layer 215 it can be positioned adjacent to, close to, or converge with a tissue site. In some applications, at least part of the second layer portion 210, of fluid constraints 220, or both, may be exposed to a tissue site through the treatment opening 230, openings 235, or both. The periphery 225 of the third layer 215 can be positioned adjacent or close to the tissue around or surrounding the tissue site. The third layer 215 may be sufficiently sticky to hold the dressing 110 in position, while also allowing the dressing 110 to be removed or repositioned without trauma to the tissue site.
[0095] [0095] Removing release liner 260 can also expose adhesive 255, and cover 125 can be attached to a fixing surface, such as the periphery 225 or another area around the treatment opening 235 and the first layer
[0096] [0096] Once the dressing 110 is in the desired position, the adhesive 255 can be pressed through the openings 235 to connect the dressing 110 to the fixing surface. The openings 235 at the edges 245 may allow adhesive 255 to flow around the edges 245 to enhance the adhesion of the edges 245 to a fixing surface.
[0097] [0097] In some embodiments, openings 235 can be sized to control the amount of adhesive 255 exposed through openings 235. For a given geometry of corners 240, the relative sizes of openings 235 can be configured to maximize the surface area of the adhesive 255 exposed and in fluid communication through openings 235 at corners 240. For example, edges 245 can intersect at substantially a right angle, or about 90 degrees, to define corners 240. In some embodiments, corners 240 may have a radius of about 10 millimeters.
[0098] [0098] In some embodiments, the bond strength of adhesive 255 may vary based on the configuration of third layer 215. For example, bond strength may vary based on the size of openings 235. In some examples, bond strength it can be inversely proportional to the size of the openings 235. In addition or alternatively, the bond strength may vary in different locations, for example, if the size of the openings 235 varies. For example, a lower bond strength in combination with larger openings 235 may provide a bond comparable to a higher bond strength in locations that have smaller openings 235.
[0099] [0099] The geometry and dimensions of the fabric interface 120, the cover 125 or both may vary to suit a specific application or anatomy. For example,
[00100] In this way, dressing 110 can provide a sealed therapeutic environment close to a tissue site, substantially isolated from the external environment, and the negative pressure source 105 can reduce pressure in the sealed therapeutic environment. The treatment opening 230 can provide an open area for distributing negative pressure and passing wound fluid through the second layer 210 and the first layer 205. The third layer 215 can provide an effective and reliable seal against difficult anatomical surfaces, such as an elbow or heel, in or around a fabric site. Additionally, dressing 110 may allow reapplication or repositioning to correct air leaks caused by creases or other discontinuities in dressing 110, for example. The ability to rectify leaks can increase the effectiveness of therapy and reduce power consumption in some modalities.
[00101] [00101] If not already configured, dressing interface 270 can be arranged over opening 275 and attached to cover 125. Fluid conductor 265 can be fluidly coupled to dressing interface 270 and the negative pressure source 105 .
[00102] [00102] The negative pressure applied through the fabric interface 120 can create a negative pressure differential through fluid restrictions 220 in the second layer
[00103] [00103] If the negative pressure source 105 is removed or turned off, the pressure differential through fluid restrictions 220 can dissipate, allowing fluid restrictions 220 to close and prevent the extrudate or other liquid from returning to the site of through the second layer 210.
[00104] [00104] In some applications, a filler can also be arranged between a tissue site and the third layer 215. For example, if the tissue site is a superficial wound, a wound filler can be applied inside the periphery, and the third layer 215 can be arranged over the periphery and the wound filler. In some embodiments, the filler may be a transmitter, such as open cell foam. The filler may comprise or consist essentially of the same material as the first layer 205 in some embodiments.
[00105] [00105] Additionally or alternatively, the installation solution or other fluid can be delivered to dressing 110, which can increase the pressure at the fabric interface 120. The increased pressure at the fabric interface 120 can create a positive pressure differential across fluid restrictions 220 in the second layer 210, which can open fluid restrictions 220 to allow the installation solution or other fluid to be delivered to the tissue site.
[00106] [00106] The systems, devices, and methods described in this document can provide significant advantages. For example, some dressings for negative pressure therapy may require time and skill to be properly sized and applied to achieve a good fit and seal. In contrast, some types of dressing 110 provide a negative pressure dressing that is simple to apply, reducing the time for application and removal. In some embodiments, for example, dressing 110 may be a fully integrated negative pressure therapy dressing that can be applied to a tissue site (including in the periphery) in one step, without being cut to size, while still providing or improving many benefits of other negative pressure therapy dressings that require scaling. Such benefits may include good transmission, beneficial granulation, protection of the peripheral tissue against maceration, protection of the tissue site against spillage of materials and a connection with little trauma and high sealing. These characteristics can be particularly advantageous for superficial wounds that have medium to high depth and exudate levels. Some modalities of dressing 110 may remain in the tissue site for at least 5 days and some modalities may remain for at least 7 days. Antimicrobial agents in dressing 110 can extend the life of dressing 110 by reducing or eliminating risks of infection that can be associated with prolonged use, particularly use with infected or highly exudative wounds.
[00107] [00107] Although shown in some illustrative modalities, an individual of ordinary skill in the art will recognize that the systems, apparatus and methods described in this document are susceptible to various changes and modifications that are within the scope of the appended claims. Furthermore, descriptions of various alternatives using terms such as "or" do not require mutual exclusivity, unless clearly required by the context, and the indefinite articles "one" or "one" do not limit the matter to a single case, unless that clearly required by the context. Components can also be combined or eliminated in various configurations for purposes of sale, manufacture, assembly or use. For example, in some configurations, dressing 110, container 115 or both can be disposed of or separated from other components for manufacture or sale. In other exemplary configurations, controller 130 can also be manufactured, configured, assembled or sold independently of other components.
[00108] [00108] The attached claims present innovative and inventive aspects of the matter described above, but the claims may also cover additional matter not specifically mentioned in detail.
For example, certain features, elements or aspects can be omitted from the claims if it is not necessary to distinguish innovative and inventive features from what is already known to an individual with skill.
The features, elements and aspects described in the context of some modalities can also be omitted, combined or replaced by alternative features that serve the same, equivalent or similar purposes, without departing from the scope of the invention defined by the attached claims.

权利要求:
Claims (33)
[1]
1. DRESSING TO TREAT A FABRIC SITE WITH NEGATIVE PRESSURE, characterized by comprising: a sealing layer comprising a treatment opening and a plurality of perforations around the treatment opening; a fluid control layer comprising a plurality of fluid restrictions aligned with the treatment opening; a transmitter adjacent to the fluid restrictions; and a cover comprising a film and a pressure sensitive adhesive, wherein the film is disposed on the transmitter and coupled to the sealing layer around the transmitter, and the pressure sensitive adhesive is disposed adjacent to the plurality of perforations.
[2]
2. DRESSING according to claim 1, characterized in that the fluid control layer comprises a polyurethane film.
[3]
3. DRESSING according to claim 2, characterized in that the fluid restrictions comprise cracks in the film.
[4]
4. DRESSING according to claim 3, characterized in that the slits each have a length in the range of about 2 millimeters to about 5 millimeters.
[5]
5. DRESSING according to claim 3, characterized in that the slits each have a length of about 3 millimeters.
[6]
6. DRESSING according to any one of claims 1 to 5, characterized in that the sealing layer is formed from a gel.
[7]
DRESSING according to any one of claims 1 to 6, characterized in that the sealing layer is formed from a silicone gel.
[8]
8. DRESSING according to any one of claims 1 to 7, characterized in that: the transmitter has a first edge defining a transmitter face adjacent to the fluid control layer; the fluid control layer has a second edge defining a fluid control face adjacent to the transmitter face and which is similar in shape to the transmitter face; and the transmitter face is at least as large as the fluid control face.
[9]
9. DRESSING, according to claim 8, characterized in that the fluid control face is larger than the opening for treatment.
[10]
10. DRESSING according to any one of claims 1 to 9, characterized in that at least one of the transmitter and the fluid control layer is coupled to a margin around the treatment opening.
[11]
11. DRESSING according to claim 10, characterized in that the margin has a width in the range of about 2 millimeters to about 3 millimeters.
[12]
12. DRESSING according to any one of claims 1 to 11, characterized in that the treatment opening is complementary to the transmitter.
[13]
13. DRESSING according to any one of claims 1 to 12, characterized in that the treatment opening forms a window around the transmitter.
[14]
14. DRESSING according to any one of claims 1 to 13, characterized in that the treatment opening has a width in the range of about 90 millimeters to about 110 millimeters and a length in the range of about 150 millimeters to about 160mm.
[15]
15. I THINK TO TREAT A FABRIC SITE WITH NEGATIVE PRESSURE, characterized by comprising: a transmitter; a fluid control layer comprising a plurality of fluid restrictions adjacent to the transmitter; a gel layer comprising a plurality of perforations, wherein at least some of the perforations are aligned with more than one of the fluid constraints; and a cover comprising a non-porous film and a pressure sensitive adhesive, wherein the non-porous film is disposed on the transmitter and coupled to the gel layer around the transmitter, and the pressure sensitive adhesive disposed adjacent to the plurality of perforations.
[16]
16. DRESSING according to claim 15, characterized in that the perforations are circular and have a diameter in a range of about 7 millimeters to about 9 millimeters.
[17]
17. DRESSING according to either of claims 15 or 16, characterized in that the fluid control layer comprises a polyurethane film.
[18]
18. DRESSING according to any one of claims 15 to 17, characterized in that fluid restrictions comprise cracks in the film.
[19]
19. I THINK according to claim 18, characterized in that the slits each have a length in the range of about 2 millimeters to about 5 millimeters.
[20]
20. DRESSING according to claim 19, characterized in that the slits each have a length of about 3 millimeters.
[21]
21. DRESSING according to any one of claims 15 to 20, characterized in that the perforations are circular and have a diameter in a range of about 7 millimeters to about 9 millimeters.
[22]
22. I THINK TO TREAT A FABRIC SITE WITH NEGATIVE PRESSURE, characterized by comprising: a cover that has an adhesive; a transmitter; a perforated polymer film; and a perforated silicone gel that has a treatment opening; where the cover, transmitter, perforated polymer film and perforated silicone gel are mounted in a stacked relationship with the cover and perforated silicone gel that close the transmitter, where the perforated polymer film is at least partially exposed through the treatment opening, and at least part of the adhesive is exposed through the perforated silicone gel around the treatment opening.
[23]
23. DRESSING, according to claim 22, characterized in that the treatment opening corresponds to a surface of the transmitter.
[24]
24. DRESSING according to either of Claims 22 or 23, characterized in that the treatment opening forms a support around the transmitter.
[25]
25. DRESSING according to any one of claims 22 to 24, characterized in that the opening for treatment has a width in the range of about 90 millimeters to about 110 millimeters and a length in the range of about 150 millimeters to about 160mm.
[26]
26. I THINK TO TREAT A TISSUE SITE WITH NEGATIVE PRESSURE, characterized by comprising: a transmitter; a gel layer comprising an open central window and a plurality of openings around the open central window; a fluid control layer extending through the open central window and comprising a plurality of fluid restrictions; a cover comprising a non-porous film and a pressure sensitive adhesive, in which the non-porous film is disposed on the transmitter and coupled to the gel layer around the transmitter, and the pressure sensitive adhesive disposed adjacent to the plurality of perforations.
[27]
27. DRESSING according to claim 26, characterized in that the central open window comprises an opening in the gel layer of about 20% to about 80%.
[28]
28. DRESSING according to either of claims 26 or 27, characterized in that the open central window has a width in the range of about 90 millimeters to about 110 millimeters and a length in the range of about 150 millimeters to about 160mm.
[29]
29. DRESSING according to any one of claims 26 to 28, characterized in that the open central window comprises an opening that allows fluid to enter through the fluid control layer.
[30]
30. DRESSING according to any one of claims 26 to 29, characterized in that the open central window has an area within 20% of the transmitter's surface area next to the open central window.
[31]
31. I THINK TO TREAT A TISSUE SITE WITH NEGATIVE PRESSURE, characterized by comprising: a foam transmitter for the passage of negative pressure and the passage of wound fluid; a lower surface that has an open area for distributing negative pressure and passing wound fluid through the transmitter, where the open area is surrounded by a surgical field area for sealing the tissue, where the surgical field area has an adhesive and does not include openings for the passage of negative pressure through the transmitter; and a wound contact layer of polymer film that extends through the open area on the bottom surface and has openings for the passage of negative pressure and wound fluid in the foam transmitter.
[32]
32. DRESSING, according to claim 31, characterized in that it also comprises a cover comprising a surgical field arranged on the transmitter and coupled to the surgical field area around the transmitter.
[33]
33. SYSTEMS, APPLIANCES AND METHODS characterized by being substantially as described in this document.

类似技术:

---

公开号 | 公开日 | 专利标题

---

BR112019025029A2|2020-06-23|I THINK TO TREAT A FABRIC SITE WITH NEGATIVE PRESSURE; AND SYSTEMS, APPLIANCES AND METHODS

---

US20180353662A1|2018-12-13|Composite Dressings For Improved Granulation And Reduced Maceration With Negative-Pressure Treatment

---

BR112019025031A2|2020-08-18|I think to treat a negative pressure tissue site and systems, devices and methods

---

US20190231600A1|2019-08-01|Systems, Apparatuses, And Methods For Negative-Pressure Treatment With Reduced Tissue In-Growth

---

KR20200016931A|2020-02-17|Dressing material that can be detached and attached for sticky exudates and drip infusions

---

KR20200016936A|2020-02-17|Customized composite dressing material for improving childcare and reducing smoke by using negative pressure treatment

---

US10695227B2|2020-06-30|Methods for manufacturing and assembling dual material tissue interface for negative-pressure therapy

---

US20200121509A1|2020-04-23|Peel and place dressing having a closed-cell contact layer

---

US20210267809A1|2021-09-02|Release liner with edge protection

---

US20180353338A1|2018-12-13|Customizable Composite Dressings For Improved Granulation And Reduced Maceration With Negative-Pressure Treatment

---

US20200246190A1|2020-08-06|Drape strip having selectable adhesive

---

CA3065517A1|2018-12-13|Composite dressings for improved granulation and reduced maceration with negative-pressure treatment

---

CN114173728A|2022-03-11|Customizable dressing for large area negative pressure therapy

---

US20210077302A1|2021-03-18|Peel And Place Dressing For Thick Exudate And Instillation

---

CN113710210A|2021-11-26|Transparent peeling and placing dressing for negative pressure treatment

---

WO2021148924A1|2021-07-29|Wound interface systems using microporous fluid-control layers

---

CN111670022A|2020-09-15|Peel-off and placement dressing for thick exudates and instillations

---

CN114144209A|2022-03-04|Systems, devices, and methods for negative pressure therapy with reduced tissue ingrowth and extended wear time

同族专利:

---

公开号 | 公开日

---

WO2018226744A1|2018-12-13|

---

CN111295209A|2020-06-16|

---

WO2018226746A1|2018-12-13|

---

EP3634520A1|2020-04-15|

---

CA3066065A1|2018-12-13|

---

AU2018281120A1|2020-01-02|

---

EP3634332A1|2020-04-15|

---

CA3061327A1|2018-12-13|

---

JP2020523073A|2020-08-06|

---

JP2020523083A|2020-08-06|

---

US20190231601A1|2019-08-01|

---

RU2019142320A|2021-07-09|

---

US20180353342A1|2018-12-13|

---

EP3634339A1|2020-04-15|

---

CN110799157A|2020-02-14|

---

KR20200016932A|2020-02-17|

---

CN110691573A|2020-01-14|

---

WO2018226744A8|2019-03-14|

---

AU2018281333A1|2019-10-31|

---

WO2018226630A1|2018-12-13|

---

US20180353337A1|2018-12-13|

---

US10940048B2|2021-03-09|

引用文献:

---

公开号 | 申请日 | 公开日 | 申请人 | 专利标题

---

---

US1355846A|1920-02-06|1920-10-19|David A Rannells|Medical appliance|

---

US2547758A|1949-01-05|1951-04-03|Wilmer B Keeling|Instrument for treating the male urethra|

---

US2632443A|1949-04-18|1953-03-24|Eleanor P Lesher|Surgical dressing|

---

GB692578A|1949-09-13|1953-06-10|Minnesota Mining & Mfg|Improvements in or relating to drape sheets for surgical use|

---

US2682873A|1952-07-30|1954-07-06|Johnson & Johnson|General purpose protective dressing|

---

NL189176B|1956-07-13|1900-01-01|Hisamitsu Pharmaceutical Co|PLASTER BASED ON A SYNTHETIC RUBBER.|

---

US2969057A|1957-11-04|1961-01-24|Brady Co W H|Nematodic swab|

---

US3066672A|1960-09-27|1962-12-04|Jr William H Crosby|Method and apparatus for serial sampling of intestinal juice|

---

US3367332A|1965-08-27|1968-02-06|Gen Electric|Product and process for establishing a sterile area of skin|

---

US3520300A|1967-03-15|1970-07-14|Amp Inc|Surgical sponge and suction device|

---

US3568675A|1968-08-30|1971-03-09|Clyde B Harvey|Fistula and penetrating wound dressing|

---

US3682180A|1970-06-08|1972-08-08|Coilform Co Inc|Drain clip for surgical drain|

---

BE789293Q|1970-12-07|1973-01-15|Parke Davis & Co|MEDICO-SURGICAL DRESSING FOR BURNS AND SIMILAR LESIONS|

---

US3826254A|1973-02-26|1974-07-30|Verco Ind|Needle or catheter retaining appliance|

---

DE2527706A1|1975-06-21|1976-12-30|Hanfried Dr Med Weigand|DEVICE FOR THE INTRODUCTION OF CONTRAST AGENTS INTO AN ARTIFICIAL INTESTINAL OUTLET|

---

DE2640413C3|1976-09-08|1980-03-27|Richard Wolf Gmbh, 7134 Knittlingen|Catheter monitor|

---

NL7710909A|1976-10-08|1978-04-11|Smith & Nephew|COMPOSITE STRAPS.|

---

GB1562244A|1976-11-11|1980-03-05|Lock P M|Wound dressing materials|

---

US4080970A|1976-11-17|1978-03-28|Miller Thomas J|Post-operative combination dressing and internal drain tube with external shield and tube connector|

---

US4139004A|1977-02-17|1979-02-13|Gonzalez Jr Harry|Bandage apparatus for treating burns|

---

US4184510A|1977-03-15|1980-01-22|Fibra-Sonics, Inc.|Valued device for controlling vacuum in surgery|

---

US4173046A|1977-08-10|1979-11-06|Gallagher John P|Absorptive patient underpad|

---

US4165748A|1977-11-07|1979-08-28|Johnson Melissa C|Catheter tube holder|

---

US4256109A|1978-07-10|1981-03-17|Nichols Robert L|Shut off valve for medical suction apparatus|

---

SE414994B|1978-11-28|1980-09-01|Landstingens Inkopscentral|VENKATETERFORBAND|

---

GB2047543B|1978-12-06|1983-04-20|Svedman Paul|Device for treating tissues for example skin|

---

US4266545A|1979-04-06|1981-05-12|Moss James P|Portable suction device for collecting fluids from a closed wound|

---

US4284079A|1979-06-28|1981-08-18|Adair Edwin Lloyd|Method for applying a male incontinence device|

---

US4261363A|1979-11-09|1981-04-14|C. R. Bard, Inc.|Retention clips for body fluid drains|

---

US4569348A|1980-02-22|1986-02-11|Velcro Usa Inc.|Catheter tube holder strap|

---

EP0035583B1|1980-03-11|1985-08-14|Schmid, Eduard, Dr.Dr.med.|Skin graft pressure bandage|

---

US4297995A|1980-06-03|1981-11-03|Key Pharmaceuticals, Inc.|Bandage containing attachment post|

---

US4333468A|1980-08-18|1982-06-08|Geist Robert W|Mesentery tube holder apparatus|

---

US4465485A|1981-03-06|1984-08-14|Becton, Dickinson And Company|Suction canister with unitary shut-off valve and filter features|

---

US4392853A|1981-03-16|1983-07-12|Rudolph Muto|Sterile assembly for protecting and fastening an indwelling device|

---

US4373519A|1981-06-26|1983-02-15|Minnesota Mining And Manufacturing Company|Composite wound dressing|

---

US4392858A|1981-07-16|1983-07-12|Sherwood Medical Company|Wound drainage device|

---

US4419097A|1981-07-31|1983-12-06|Rexar Industries, Inc.|Attachment for catheter tube|

---

AU550575B2|1981-08-07|1986-03-27|Richard Christian Wright|Wound drainage device|

---

SE429197B|1981-10-14|1983-08-22|Frese Nielsen|SAR TREATMENT DEVICE|

---

DE3146266A1|1981-11-21|1983-06-01|B. Braun Melsungen Ag, 3508 Melsungen|COMBINED DEVICE FOR A MEDICAL SUCTION DRAINAGE|

---

US4551139A|1982-02-08|1985-11-05|Marion Laboratories, Inc.|Method and apparatus for burn wound treatment|

---

US4475909A|1982-05-06|1984-10-09|Eisenberg Melvin I|Male urinary device and method for applying the device|

---

EP0100148B1|1982-07-06|1986-01-08|Dow Corning Limited|Medical-surgical dressing and a process for the production thereof|

---

NZ206837A|1983-01-27|1986-08-08|Johnson & Johnson Prod Inc|Thin film adhesive dressing:backing material in three sections|

---

US4548202A|1983-06-20|1985-10-22|Ethicon, Inc.|Mesh tissue fasteners|

---

US4540412A|1983-07-14|1985-09-10|The Kendall Company|Device for moist heat therapy|

---

US4543100A|1983-11-01|1985-09-24|Brodsky Stuart A|Catheter and drain tube retainer|

---

US4525374A|1984-02-27|1985-06-25|Manresa, Inc.|Treating hydrophobic filters to render them hydrophilic|

---

GB2157958A|1984-05-03|1985-11-06|Ernest Edward Austen Bedding|Ball game net support|

---

US4897081A|1984-05-25|1990-01-30|Thermedics Inc.|Percutaneous access device|

---

US5215522A|1984-07-23|1993-06-01|Ballard Medical Products|Single use medical aspirating device and method|

---

GB8419745D0|1984-08-02|1984-09-05|Smith & Nephew Ass|Wound dressing|

---

US4872450A|1984-08-17|1989-10-10|Austad Eric D|Wound dressing and method of forming same|

---

GB8422492D0|1984-09-06|1984-10-10|Smith & Nephew Ass|Adhesive dressing|

---

US4826494A|1984-11-09|1989-05-02|Stryker Corporation|Vacuum wound drainage system|

---

US4655754A|1984-11-09|1987-04-07|Stryker Corporation|Vacuum wound drainage system and lipids baffle therefor|

---

US4605399A|1984-12-04|1986-08-12|Complex, Inc.|Transdermal infusion device|

---

US5037397A|1985-05-03|1991-08-06|Medical Distributors, Inc.|Universal clamp|

---

US4640688A|1985-08-23|1987-02-03|Mentor Corporation|Urine collection catheter|

---

US4710165A|1985-09-16|1987-12-01|Mcneil Charles B|Wearable, variable rate suction/collection device|

---

US4758220A|1985-09-26|1988-07-19|Alcon Laboratories, Inc.|Surgical cassette proximity sensing and latching apparatus|

---

US4733659A|1986-01-17|1988-03-29|Seton Company|Foam bandage|

---

WO1987004626A1|1986-01-31|1987-08-13|Osmond, Roger, L., W.|Suction system for wound and gastro-intestinal drainage|

---

US4838883A|1986-03-07|1989-06-13|Nissho Corporation|Urine-collecting device|

---

JPH0333027B2|1986-05-29|1991-05-15|Terumo Corp|

---

GB8621884D0|1986-09-11|1986-10-15|Bard Ltd|Catheter applicator|

---

GB2195255B|1986-09-30|1991-05-01|Vacutec Uk Limited|Apparatus for vacuum treatment of an epidermal surface|

---

US4743232A|1986-10-06|1988-05-10|The Clinipad Corporation|Package assembly for plastic film bandage|

---

DE3634569A1|1986-10-10|1988-04-21|Sachse Hans E|CONDOM CATHETER, A URINE TUBE CATHETER FOR PREVENTING RISING INFECTIONS|

---

JPH0363913B2|1986-11-26|1991-10-03|Toshiro Tachibana|

---

GB8628564D0|1986-11-28|1987-01-07|Smiths Industries Plc|Anti-foaming agent suction apparatus|

---

GB8706116D0|1987-03-14|1987-04-15|Smith & Nephew Ass|Adhesive dressings|

---

US4787888A|1987-06-01|1988-11-29|University Of Connecticut|Disposable piezoelectric polymer bandage for percutaneous delivery of drugs and method for such percutaneous delivery |

---

US4863449A|1987-07-06|1989-09-05|Hollister Incorporated|Adhesive-lined elastic condom cathether|

---

US5176663A|1987-12-02|1993-01-05|Pal Svedman|Dressing having pad with compressibility limiting elements|

---

US4906240A|1988-02-01|1990-03-06|Matrix Medica, Inc.|Adhesive-faced porous absorbent sheet and method of making same|

---

US4985019A|1988-03-11|1991-01-15|Michelson Gary K|X-ray marker|

---

GB8812803D0|1988-05-28|1988-06-29|Smiths Industries Plc|Medico-surgical containers|

---

US4919654A|1988-08-03|1990-04-24|Kalt Medical Corporation|IV clamp with membrane|

---

US5000741A|1988-08-22|1991-03-19|Kalt Medical Corporation|Transparent tracheostomy tube dressing|

---

EP0379416B1|1989-01-16|1995-03-08|Roussel-Uclaf|Azabicycloheptene derivatives and their salts, process for their preparation, their use as medicaments and compositions containing them|

---

CA2009085A1|1989-02-27|1990-08-27|Rohitkumar H. Vora|Coatings of intermediate molecular weight polyimides|

---

GB8906100D0|1989-03-16|1989-04-26|Smith & Nephew|Laminates|

---

US5100396A|1989-04-03|1992-03-31|Zamierowski David S|Fluidic connection system and method|

---

US5527293A|1989-04-03|1996-06-18|Kinetic Concepts, Inc.|Fastening system and method|

---

US4969880A|1989-04-03|1990-11-13|Zamierowski David S|Wound dressing and treatment method|

---

US5261893A|1989-04-03|1993-11-16|Zamierowski David S|Fastening system and method|

---

US5358494A|1989-07-11|1994-10-25|Svedman Paul|Irrigation dressing|

---

JP2719671B2|1989-07-11|1998-02-25|日本ゼオン株式会社|Wound dressing|

---

US5232453A|1989-07-14|1993-08-03|E. R. Squibb & Sons, Inc.|Catheter holder|

---

GB2235877A|1989-09-18|1991-03-20|Antonio Talluri|Closed wound suction apparatus|

---

US5134994A|1990-02-12|1992-08-04|Say Sam L|Field aspirator in a soft pack with externally mounted container|

---

US5092858A|1990-03-20|1992-03-03|Becton, Dickinson And Company|Liquid gelling agent distributor device|

---

US5149331A|1991-05-03|1992-09-22|Ariel Ferdman|Method and device for wound closure|

---

US5278100A|1991-11-08|1994-01-11|Micron Technology, Inc.|Chemical vapor deposition technique for depositing titanium silicide on semiconductor wafers|

---

US5636643A|1991-11-14|1997-06-10|Wake Forest University|Wound treatment employing reduced pressure|

---

US5645081A|1991-11-14|1997-07-08|Wake Forest University|Method of treating tissue damage and apparatus for same|

---

US5279550A|1991-12-19|1994-01-18|Gish Biomedical, Inc.|Orthopedic autotransfusion system|

---

US5167613A|1992-03-23|1992-12-01|The Kendall Company|Composite vented wound dressing|

---

SE500972C2|1992-03-30|1994-10-10|Moelnlycke Ab|Method and apparatus for manufacturing wound dressings and a wound dressing made by the method|

---

FR2690617B1|1992-04-29|1994-06-24|Cbh Textile|TRANSPARENT ADHESIVE DRESSING.|

---

DE4306478A1|1993-03-02|1994-09-08|Wolfgang Dr Wagner|Drainage device, in particular pleural drainage device, and drainage method|

---

US5342376A|1993-05-03|1994-08-30|Dermagraphics, Inc.|Inserting device for a barbed tissue connector|

---

US6241747B1|1993-05-03|2001-06-05|Quill Medical, Inc.|Barbed Bodily tissue connector|

---

US5344415A|1993-06-15|1994-09-06|Deroyal Industries, Inc.|Sterile system for dressing vascular access site|

---

US5437651A|1993-09-01|1995-08-01|Research Medical, Inc.|Medical suction apparatus|

---

US5466231A|1993-11-04|1995-11-14|Merocel Corporation|Laminated sponge device|

---

US5549584A|1994-02-14|1996-08-27|The Kendall Company|Apparatus for removing fluid from a wound|

---

US5607388A|1994-06-16|1997-03-04|Hercules Incorporated|Multi-purpose wound dressing|

---

US5556375A|1994-06-16|1996-09-17|Hercules Incorporated|Wound dressing having a fenestrated base layer|

---

US5664270A|1994-07-19|1997-09-09|Kinetic Concepts, Inc.|Patient interface system|

---

AU698477B2|1994-08-22|1998-10-29|Kci Licensing, Inc.|Wound drainage equipment|

---

TW330217B|1994-12-20|1998-04-21|Kimberly Clark Co|Low gauge films and film/nonwoven laminates|

---

DE29504378U1|1995-03-15|1995-09-14|Mtg Medizinisch Tech Geraeteba|Electronically controlled low-vacuum pump for chest and wound drainage|

---

US5783026A|1995-05-24|1998-07-21|International Business Machines Corporation|Apparatus for stacking sheets by carriers|

---

GB9523253D0|1995-11-14|1996-01-17|Mediscus Prod Ltd|Portable wound treatment apparatus|

---

GB2324732B|1997-05-02|2001-09-26|Johnson & Johnson Medical|Absorbent wound dressings|

---

US6135116A|1997-07-28|2000-10-24|Kci Licensing, Inc.|Therapeutic method for treating ulcers|

---

GB9719520D0|1997-09-12|1997-11-19|Kci Medical Ltd|Surgical drape and suction heads for wound treatment|

---

AU755496B2|1997-09-12|2002-12-12|Kci Licensing, Inc.|Surgical drape and suction head for wound treatment|

---

US6071267A|1998-02-06|2000-06-06|Kinetic Concepts, Inc.|Medical patient fluid management interface system and method|

---

US6488643B1|1998-10-08|2002-12-03|Kci Licensing, Inc.|Wound healing foot wrap|

---

US6287316B1|1999-03-26|2001-09-11|Ethicon, Inc.|Knitted surgical mesh|

---

EP1257313B1|2000-02-24|2004-05-12|Venetec International, Inc.|Universal catheter anchoring system|

---

US20040148756A1|2002-09-09|2004-08-05|Pommer Richard J.|Alignment plate with matched thermal coefficient of expansion|

---

GB0011202D0|2000-05-09|2000-06-28|Kci Licensing Inc|Abdominal wound dressing|

---

US6856821B2|2000-05-26|2005-02-15|Kci Licensing, Inc.|System for combined transcutaneous blood gas monitoring and vacuum assisted wound closure|

---

US6855135B2|2000-11-29|2005-02-15|Hill-Rom Services, Inc.|Vacuum therapy and cleansing dressing for wounds|

---

US6685681B2|2000-11-29|2004-02-03|Hill-Rom Services, Inc.|Vacuum therapy and cleansing dressing for wounds|

---

US6991643B2|2000-12-20|2006-01-31|Usgi Medical Inc.|Multi-barbed device for retaining tissue in apposition and methods of use|

---

US7700819B2|2001-02-16|2010-04-20|Kci Licensing, Inc.|Biocompatible wound dressing|

---

US6540705B2|2001-02-22|2003-04-01|Core Products International, Inc.|Ankle brace providing upper and lower ankle adjustment|

---

US7799004B2|2001-03-05|2010-09-21|Kci Licensing, Inc.|Negative pressure wound treatment apparatus and infection identification system and method|

---

US7645269B2|2001-04-30|2010-01-12|Kci Licensing, Inc.|Gradient wound treatment system and method|

---

WO2003057071A2|2001-12-26|2003-07-17|Hill-Rom Services, Inc.|Vacuum bandage packing|

---

AU2002359828A1|2001-12-26|2003-07-24|Hill-Rom Services Inc.|Vented vacuum bandage and method|

---

CA2477674A1|2002-02-28|2003-09-12|Jeffrey S. Lockwood|External catheter access to vacuum bandage|

---

EP1496822B1|2002-04-10|2018-08-29|KCI Medical Resources|Access openings in vacuum bandage|

---

US7846141B2|2002-09-03|2010-12-07|Bluesky Medical Group Incorporated|Reduced pressure treatment system|

---

GB0224986D0|2002-10-28|2002-12-04|Smith & Nephew|Apparatus|

---

US7227050B2|2002-12-31|2007-06-05|Ossur Hf|Method for producing a wound dressing|

---

GB0325126D0|2003-10-28|2003-12-03|Smith & Nephew|Apparatus with heat|

---

GB0325120D0|2003-10-28|2003-12-03|Smith & Nephew|Apparatus with actives|

---

US7909805B2|2004-04-05|2011-03-22|Bluesky Medical Group Incorporated|Flexible reduced pressure treatment appliance|

---

US8529548B2|2004-04-27|2013-09-10|Smith & Nephew Plc|Wound treatment apparatus and method|

---

US20070021697A1|2004-07-26|2007-01-25|Kci Licensing, Inc.|System and method for use of agent in combination with subatmospheric tissue treatment|

---

US7161056B2|2005-01-28|2007-01-09|Ossur Hf|Wound dressing and method for manufacturing the same|

---

US8337980B2|2005-05-20|2012-12-25|Charlie Hubbs|Silicone-impregnated foam product and method for producing same|

---

GB0606661D0|2006-04-03|2006-05-10|Brightwake Ltd|Improvements relating to dressings|

---

WO2008040020A2|2006-09-28|2008-04-03|Puricore, Inc.|Apparatus and method for wound, cavity, and bone treatment|

---

MX2009008396A|2007-02-09|2009-10-28|Kci Licensing Inc|A breathable interface system for topical reduced pressure.|

---

GB2452720A|2007-09-11|2009-03-18|Ethicon Inc|Wound dressing with an antimicrobial absorbent layer and an apertured cover sheet|

---

US8449508B2|2008-03-05|2013-05-28|Kci Licensing, Inc.|Dressing and method for applying reduced pressure to and collecting and storing fluid from a tissue site|

---

US8152785B2|2008-03-13|2012-04-10|Tyco Healthcare Group Lp|Vacuum port for vacuum wound therapy|

---

EP2305328B1|2008-05-30|2017-11-01|KCI Licensing, Inc.|Reduced pressure, compression systems and apparatuses for use on joints|

---

US8007481B2|2008-07-17|2011-08-30|Tyco Healthcare Group Lp|Subatmospheric pressure mechanism for wound therapy system|

---

US8021347B2|2008-07-21|2011-09-20|Tyco Healthcare Group Lp|Thin film wound dressing|

---

US8460698B2|2008-08-01|2013-06-11|Milliken & Company|Composite article suitable for use as a wound dressing|

---

CA2731427C|2008-08-08|2020-01-28|Tyco Healthcare Group Lp|Wound dressing of continuous fibers|

---

GB0815078D0|2008-08-18|2008-09-24|Inotec Amd Ltd|Hyperbaric dressing and method|

---

US9414968B2|2008-09-05|2016-08-16|Smith & Nephew, Inc.|Three-dimensional porous film contact layer with improved wound healing|

---

JP5547197B2|2008-09-18|2014-07-09|ケーシーアイライセンシングインコーポレイテッド|Multilayer dressing, system, and method for applying reduced pressure to a tissue site|

---

GB0821702D0|2008-11-28|2008-12-31|Brightwake Ltd|Process|

---

US8216198B2|2009-01-09|2012-07-10|Tyco Healthcare Group Lp|Canister for receiving wound exudate in a negative pressure therapy system|

---

GB2468905B|2009-03-27|2013-12-11|Brightwake Ltd|Wound packing material|

---

KR101086653B1|2009-04-24|2011-11-24|알케어캄파니리미티드|Article for treating wound and method for manufacturing the same|

---

US8251979B2|2009-05-11|2012-08-28|Tyco Healthcare Group Lp|Orientation independent canister for a negative pressure wound therapy device|

---

US8469936B2|2009-07-15|2013-06-25|Kci Licensing, Inc.|Reduced-pressure dressings, systems, and methods employing desolidifying barrier layers|

---

US8690844B2|2009-08-27|2014-04-08|Kci Licensing, Inc.|Re-epithelialization wound dressings and systems|

---

EP2506815B1|2009-12-03|2019-07-24|Pharmaplast SAE|A wound dressing, and method and production line of producing the wound dressing|

---

US8791315B2|2010-02-26|2014-07-29|Smith & Nephew, Inc.|Systems and methods for using negative pressure wound therapy to manage open abdominal wounds|

---

US8721606B2|2010-03-11|2014-05-13|Kci Licensing, Inc.|Dressings, systems, and methods for treating a tissue site|

---

US8454580B2|2010-03-12|2013-06-04|Kci Licensing, Inc.|Adjustable reduced-pressure wound coverings|

---

WO2011115229A1|2010-03-17|2011-09-22|株式会社ビー・アイ・テック|Stem structure for composite prosthetic hip and method for manufacturing the same|

---

US9999702B2|2010-04-09|2018-06-19|Kci Licensing Inc.|Apparatuses, methods, and compositions for the treatment and prophylaxis of chronic wounds|

---

US9061095B2|2010-04-27|2015-06-23|Smith & Nephew Plc|Wound dressing and method of use|

---

GB201006985D0|2010-04-27|2010-06-09|Smith & Nephew|Wound dressing|

---

GB201008347D0|2010-05-19|2010-07-07|Smith & Nephew|Wound protection|

---

US9352075B2|2010-12-07|2016-05-31|Kci Licensing, Inc.|Wound healing apparatus for promoting granulation and epithelialization at a tissue site|

---

US8613733B2|2010-12-15|2013-12-24|Kci Licensing, Inc.|Foam dressing with integral porous film|

---

US9107990B2|2011-02-14|2015-08-18|Kci Licensing, Inc.|Reduced-pressure dressings, systems, and methods for use with linear wounds|

---

GB201108229D0|2011-05-17|2011-06-29|Smith & Nephew|Tissue healing|

---

EP2532325B1|2011-06-09|2014-03-05|Paul Hartmann AG|Wound dressing comprising foam and cream base and swelling material for negative pressure therapy|

---

WO2013066426A2|2011-06-24|2013-05-10|Kci Licensing, Inc.|Reduced-pressure dressings employing tissue-fixation elements|

---

EP2545943A1|2011-07-12|2013-01-16|Dr. Suwelack Skin & Health Care AG|Perforated, coated wound healing material|

---

GB2493960B|2011-08-25|2013-09-18|Brightwake Ltd|Non-adherent wound dressing|

---

DK2572737T3|2011-09-26|2016-06-27|Bsn Medical Gmbh|improved wound dressing|

---

US9308713B2|2011-10-07|2016-04-12|Hughes Network Systems, Llc|Method and apparatus for assembly of a satellite antenna|

---

JP6250571B2|2012-03-12|2017-12-20|スミス アンド ネフュー ピーエルシーＳｍｉｔｈ ＆ Ｎｅｐｈｅｗ Ｐｕｂｌｉｃ Ｌｉｍｉｔｅｄ Ｃｏｍｐａｎｙ|Pressure reducing apparatus and method|

---

EP3354293B1|2012-05-23|2019-12-11|Smith & Nephew plc|Apparatuses for negative pressure wound therapy|

---

EP3403624B1|2012-07-30|2020-09-02|KCI Licensing, Inc.|Reduced-pressure absorbent dressing, system for treating a tissue site, and method of manufacturing the dressing|

---

US9345869B2|2012-10-11|2016-05-24|Owl Manor Medical, Llc|Oxygen diffusive wound dressings and methods of manufacturing and use|

---

WO2014107233A1|2013-01-02|2014-07-10|Kci Licensing, Inc.|A medical drape having an ultra-thin drape film and a thick adhesive coating|

---

DE102013100157A1|2013-01-09|2014-07-10|Birgit Riesinger|Liquid-permeable primary dressing with a silicone coating|

---

EP2945659B1|2013-01-16|2019-10-30|KCI Licensing, Inc.|Ion exchange enhanced absorbent systems|

---

DE102013002521A1|2013-02-13|2014-08-14|Paul Hartmann Ag|Abdominal wound pad with lanyard|

---

EP3372209A1|2013-03-13|2018-09-12|Smith & Nephew, Inc.|Negative pressure wound closure device and systems and methods of use in treating wounds with negative pressure|

---

RU2015143729A|2013-03-15|2017-04-21|СМИТ ЭНД НЕФЬЮ ПиЭлСи|Wound dressing and method of treatment|

---

CA2902396A1|2013-03-15|2014-09-18|Smith & Nephew Plc|Wound dressing sealant and use thereof|

---

US10058455B2|2013-06-10|2018-08-28|Ultramend, Inc.|Nano-enhanced wound dressing|

---

EP2815731A1|2013-06-18|2014-12-24|Mölnlycke Health Care AB|Fluid transport dressing|

---

CN105530898B|2013-07-16|2020-02-28|史密夫及内修公开有限公司|Apparatus for wound therapy|

---

EP3038667B1|2013-08-26|2019-10-09|KCI Licensing, Inc.|Dressing interface with moisture controlling feature and sealing function|

---

GB201317742D0|2013-10-08|2013-11-20|Smith & Nephew|Ph indicator dressing|

---

EP3173054B1|2013-10-30|2018-04-25|KCI Licensing, Inc.|Dressing with diffrentially sized perforations|

---

EP3656362A1|2013-10-30|2020-05-27|KCI Licensing, Inc.|Condensate absorbing and dissipating system related application|

---

EP3744361A1|2013-10-30|2020-12-02|KCI Licensing, Inc.|Absorbent conduit and system|

---

WO2015168681A1|2014-05-02|2015-11-05|Kci Licensing, Inc.|Fluid storage devices, systems, and methods|

---

EP3797744A1|2014-05-09|2021-03-31|3M Innovative Properties Company|Dressing with contracting layer for linear tissue sites|

---

WO2015173547A1|2014-05-14|2015-11-19|Brightwake Limited|Wound dressing|

---

CA2952284A1|2014-06-18|2015-12-23|Smith & Nephew Plc|Wound dressing|

---

US11007082B2|2014-07-23|2021-05-18|Innovative Therapies Inc.|Foam laminate dressing|

---

CN112121243A|2014-07-24|2020-12-25|凯希特许有限公司|Combined fluid instillation and negative pressure dressing|

---

US9724845B2|2014-11-13|2017-08-08|The Boeing Company|Systems and methods for making indexed prepreg composite sheets and laminated composite articles|

---

EP3023083A1|2014-11-20|2016-05-25|Mölnlycke Health Care AB|Wound dressings|

---

EP3900685A4|2015-01-14|2021-10-27|3M Innovative Properties Co|Closed abdominal manifold dressing|

---

US11096830B2|2015-09-01|2021-08-24|Kci Licensing, Inc.|Dressing with increased apposition force|

---

US10973694B2|2015-09-17|2021-04-13|Kci Licensing, Inc.|Hybrid silicone and acrylic adhesive cover for use with wound treatment|

---

DE202015006570U1|2015-09-17|2015-10-15|Lohmann & Rauscher Gmbh|Wound care arrangement|

---

US20170095374A1|2015-10-05|2017-04-06|Daniel Stuart Lauer|Hemostatic bandage for mucosal membranes, kit containing the same, and method of using the same|

---

CA3010496A1|2016-01-06|2017-07-13|Kci Licensing, Inc.|System and methods for the treatment of wounds with dressing having closed cells|

---

SE540964C2|2016-08-23|2019-01-29|Halao Ab|Wound dressing with inflatable structures|

---

CN106390213A|2016-08-29|2017-02-15|唐山市博世德医疗器械有限公司|Multifunctional silica gel negative-pressure drainage device and manufacturing method thereof|GB201020236D0|2010-11-30|2011-01-12|Convatec Technologies Inc|A composition for detecting biofilms on viable tissues|

---

ES2748519T3|2010-12-08|2020-03-17|Convatec Technologies Inc|Wound exudate system accessory|

---

EP2648793B1|2010-12-08|2020-03-11|ConvaTec Technologies Inc.|Integrated system for assessing wound exudates|

---

WO2013066426A2|2011-06-24|2013-05-10|Kci Licensing, Inc.|Reduced-pressure dressings employing tissue-fixation elements|

---

GB2497406A|2011-11-29|2013-06-12|Webtec Converting Llc|Dressing with a perforated binder layer|

---

WO2018009873A1|2016-07-08|2018-01-11|Convatec Technologies Inc.|Fluid collection apparatus|

---

CN113727686A|2019-04-24|2021-11-30|凯希特许有限公司|Hybrid adhesive tissue cover with applied stretch|

---

WO2020256843A1|2019-06-20|2020-12-24|Kci Licensing, Inc.|Peel and place dressing for negative-pressure therapy|

---

WO2021001737A1|2019-07-03|2021-01-07|Kci Licensing, Inc.|Customizable dressings for negative-pressure treatment of large areas|

---

WO2021019371A1|2019-07-26|2021-02-04|Kci Licensing, Inc.|Antimicrobial/antibacterial disruptive dressing for use with negative pressure and fluid instillation|

---

WO2021019460A1|2019-07-30|2021-02-04|Kci Licensing, Inc.|Negative-pressure dressing for foot treatment|

---

WO2021024165A1|2019-08-08|2021-02-11|Kci Licensing, Inc.|Tissue interface with fold-retaining fastener|

---

BR202019024885U2|2019-11-26|2021-06-08|Gustavo Moreira Costa De Souza|dressing for negative pressure wound therapy|

---

WO2021116977A1|2019-12-13|2021-06-17|Kci Licensing, Inc.|Conformable dressing for negative-pressure treatment of large areas|

---

WO2021140468A1|2020-01-09|2021-07-15|Kci Licensing, Inc.|Systems and apparatuses for wound cleansing and tissue deformation|

---

WO2021148925A1|2020-01-21|2021-07-29|Kci Licensing, Inc.|Customizable negative-pressure tissue interface with edge protection|

法律状态:
2021-07-13| B25A| Requested transfer of rights approved|Owner name: 3M INNOVATIVE PROPERTIES COMPANY (US) |

---

2021-11-03| B350| Update of information on the portal [chapter 15.35 patent gazette]|

优先权:

---

申请号 | 申请日 | 专利标题

---

US201762516550P| true| 2017-06-07|2017-06-07|

---

US201762516540P| true| 2017-06-07|2017-06-07|

---

US201762516566P| true| 2017-06-07|2017-06-07|

---

US62/516,566|2017-06-07|

---

US62/516,540|2017-06-07|

---

US62/516,550|2017-06-07|

---

US201762565754P| true| 2017-09-29|2017-09-29|

---

US62/565,754|2017-09-29|

---

US201762576498P| true| 2017-10-24|2017-10-24|

---

US62/576,498|2017-10-24|

---

US201762592950P| true| 2017-11-30|2017-11-30|

---

US62/592,950|2017-11-30|

---

US201862613494P| true| 2018-01-04|2018-01-04|

---

US62/613,494|2018-01-04|

---

US201862615821P| true| 2018-01-10|2018-01-10|

---

US62/615,821|2018-01-10|

---

US201862616244P| true| 2018-01-11|2018-01-11|

---

US62/616,244|2018-01-11|

---

US201862623325P| true| 2018-01-29|2018-01-29|

---

US62/623,325|2018-01-29|

---

US201862625704P| true| 2018-02-02|2018-02-02|

---

US62/625,704|2018-02-02|

---

US201862633438P| true| 2018-02-21|2018-02-21|

---

US62/633,438|2018-02-21|

---

US201862650572P| true| 2018-03-30|2018-03-30|

---

US62/650,572|2018-03-30|

---

PCT/US2018/036132|WO2018226746A1|2017-06-07|2018-06-05|Peel and place dressing for negative-pressure therapy|

---